SONN · Sonnet BioTherapeutics
Acquired Company
Chanticleer Holdings, Inc. completed its merger with Sonnet BioTherapeutics, Inc. on April 1, 2020, after which Sonnet became a wholly owned subsidiary of Chanticleer.
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotech company, develops a platform for single-acting or bispecific biologics. The company is headquartered in Princeton, New Jersey.
100 OVERLOOK CENTER, PRINCETON, NJ, UNITED STATES, 08540, Princeton, NJ, 08540, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
8.603M
52 Wk Range
$1.08 - $10.38
Previous Close
$3.10
Open
$3.16
Volume
10,456,154
Day Range
$1.26 - $3.23
Enterprise Value
8.35M
Cash
321.3K
Avg Qtr Burn
-1.759M
Insider Ownership
4.25%
Institutional Own.
9.95%
Qtr Updated
Jun 30th 2025